Together, these results indicate that blocking the checkpoint receptor LILRB1 is a potential strategy to restore host NK cell-dependent anti-Mtb immune responses without causing exaggerated inflammation, paving the way to develop TB immunotherapy that may provide therapeutic potential alone or in combination with antibiotic treatment. The gene discussed is LILRB1; the disease is tuberculosis.